July 8 (Reuters) - Merck & Co Inc MRK.N :
* ZYMEWORKS - CO & MERCK SIGNED NEW LICENSE AGREEMENT
* ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULTISPECIFIC ANTIBODY THERAPEUTIC CANDIDATES USING CO'S AZYMETRIC & EFECT PLATFORMS
* ZYMEWORKS - TO PROVIDE MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, COMMERCIALIZE UP TO 3 NEW MULTISPECIFIC ANTIBODIES FOR MERCK'S THERAPEUTIC TARGETS
* ZYMEWORKS INC - CO WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT
* ZYMEWORKS - IF EACH OF 3 PROGRAMS YIELD APPROVED PRODUCT, CO ELIGIBLE TO RECEIVE UP TO US$411 MILLION IN OPTION EXERCISE FEES & MILESTONE PAYMENTS
* ZYMEWORKS - IF EACH OF 3 PROGRAMS YIELD APPROVED PRODUCT, CO ELIGIBLE TO RECEIVE UP TO US$480 MILLION IN COMMERCIAL MILESTONE PAYMENTS, ROYALTIES ON SALES
* ZYMEWORKS INC - NEW AGREEMENT DOES NOT IMPACT ORIGINAL AGREEMENT BETWEEN CO & MERCK